FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1978111504> ?p ?o ?g. }

• W1978111504 endingPage "1121" @default.
• W1978111504 startingPage "1114" @default.
• W1978111504 abstract "Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor, epidermal growth factor receptor (EGFR), and RET signaling. This placebo-controlled trial assessed whether vandetanib conferred an overall survival benefit in patients with advanced non-small-cell lung cancer (NSCLC) after prior treatment with an EGFR tyrosine kinase inhibitor and one or two chemotherapy regimens.Eligible patients were randomly assigned 2:1 to receive vandetanib 300 mg/d or placebo until disease progression or unacceptable toxicity. The primary objective was to compare the outcomes between the two arms with respect to overall survival.Overall, 924 patients received vandetanib (n = 617) or placebo (n = 307). No significant increase in overall survival was detected in the vandetanib cohort compared with placebo (hazard ratio = 0.95; 95.2% CI, 0.81 to 1.11; P = .527); median overall survival was 8.5 months versus 7.8 months for vandetanib and placebo patients, respectively. Statistically significant advantages favoring vandetanib were observed for progression-free survival (hazard ratio = 0.63; P < .001) and objective response rate (2.6% v 0.7%; P = .028). Postprogression therapy was balanced across the cohorts in both number and type. Adverse events were generally consistent with previous NSCLC studies of vandetanib 300 mg; common events occurring with a greater frequency in the vandetanib arm versus placebo included diarrhea (46% v 11%), rash (42% v 11%), and hypertension (26% v 3%).The study did not demonstrate an overall survival benefit for vandetanib versus placebo. There was a higher incidence of some adverse events with vandetanib." @default.
• W1978111504 created "2016-06-24" @default.
• W1978111504 creator A5004217843 @default.
• W1978111504 creator A5007889470 @default.
• W1978111504 creator A5008880845 @default.
• W1978111504 creator A5024942208 @default.
• W1978111504 creator A5028055906 @default.
• W1978111504 creator A5030107272 @default.
• W1978111504 creator A5040480389 @default.
• W1978111504 creator A5043397424 @default.
• W1978111504 creator A5043672686 @default.
• W1978111504 creator A5055974749 @default.
• W1978111504 date "2012-04-01" @default.
• W1978111504 modified "2023-09-28" @default.
• W1978111504 title "Vandetanib Versus Placebo in Patients With Advanced Non–Small-Cell Lung Cancer After Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor: A Randomized, Double-Blind Phase III Trial (ZEPHYR)" @default.
• W1978111504 cites W1988442083 @default.
• W1978111504 cites W1998482951 @default.
• W1978111504 cites W2006994284 @default.
• W1978111504 cites W2014725195 @default.
• W1978111504 cites W2020830322 @default.
• W1978111504 cites W2100777892 @default.
• W1978111504 cites W2102590541 @default.
• W1978111504 cites W2108042184 @default.
• W1978111504 cites W2109833554 @default.
• W1978111504 cites W2111710483 @default.
• W1978111504 cites W2114940128 @default.
• W1978111504 cites W2115078104 @default.
• W1978111504 cites W2120718661 @default.
• W1978111504 cites W2122553809 @default.
• W1978111504 cites W2124464299 @default.
• W1978111504 cites W2127809030 @default.
• W1978111504 cites W2138297714 @default.
• W1978111504 cites W2145854263 @default.
• W1978111504 cites W2146404049 @default.
• W1978111504 cites W2147289344 @default.
• W1978111504 cites W2150335765 @default.
• W1978111504 cites W2153477391 @default.
• W1978111504 cites W2166084034 @default.
• W1978111504 doi "https://doi.org/10.1200/jco.2011.36.1709" @default.
• W1978111504 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22370318" @default.
• W1978111504 hasPublicationYear "2012" @default.
• W1978111504 type Work @default.
• W1978111504 sameAs 1978111504 @default.
• W1978111504 citedByCount "208" @default.
• W1978111504 countsByYear W19781115042012 @default.
• W1978111504 countsByYear W19781115042013 @default.
• W1978111504 countsByYear W19781115042014 @default.
• W1978111504 countsByYear W19781115042015 @default.
• W1978111504 countsByYear W19781115042016 @default.
• W1978111504 countsByYear W19781115042017 @default.
• W1978111504 countsByYear W19781115042018 @default.
• W1978111504 countsByYear W19781115042019 @default.
• W1978111504 countsByYear W19781115042020 @default.
• W1978111504 countsByYear W19781115042021 @default.
• W1978111504 countsByYear W19781115042022 @default.
• W1978111504 countsByYear W19781115042023 @default.
• W1978111504 crossrefType "journal-article" @default.
• W1978111504 hasAuthorship W1978111504A5004217843 @default.
• W1978111504 hasAuthorship W1978111504A5007889470 @default.
• W1978111504 hasAuthorship W1978111504A5008880845 @default.
• W1978111504 hasAuthorship W1978111504A5024942208 @default.
• W1978111504 hasAuthorship W1978111504A5028055906 @default.
• W1978111504 hasAuthorship W1978111504A5030107272 @default.
• W1978111504 hasAuthorship W1978111504A5040480389 @default.
• W1978111504 hasAuthorship W1978111504A5043397424 @default.
• W1978111504 hasAuthorship W1978111504A5043672686 @default.
• W1978111504 hasAuthorship W1978111504A5055974749 @default.
• W1978111504 hasConcept C121608353 @default.
• W1978111504 hasConcept C126322002 @default.
• W1978111504 hasConcept C142724271 @default.
• W1978111504 hasConcept C143998085 @default.
• W1978111504 hasConcept C170493617 @default.
• W1978111504 hasConcept C197934379 @default.
• W1978111504 hasConcept C204787440 @default.
• W1978111504 hasConcept C207103383 @default.
• W1978111504 hasConcept C27081682 @default.
• W1978111504 hasConcept C2776256026 @default.
• W1978111504 hasConcept C2778820342 @default.
• W1978111504 hasConcept C2779438470 @default.
• W1978111504 hasConcept C2780333294 @default.
• W1978111504 hasConcept C42362537 @default.
• W1978111504 hasConcept C44249647 @default.
• W1978111504 hasConcept C71924100 @default.
• W1978111504 hasConcept C90924648 @default.
• W1978111504 hasConceptScore W1978111504C121608353 @default.
• W1978111504 hasConceptScore W1978111504C126322002 @default.
• W1978111504 hasConceptScore W1978111504C142724271 @default.
• W1978111504 hasConceptScore W1978111504C143998085 @default.
• W1978111504 hasConceptScore W1978111504C170493617 @default.
• W1978111504 hasConceptScore W1978111504C197934379 @default.
• W1978111504 hasConceptScore W1978111504C204787440 @default.
• W1978111504 hasConceptScore W1978111504C207103383 @default.
• W1978111504 hasConceptScore W1978111504C27081682 @default.
• W1978111504 hasConceptScore W1978111504C2776256026 @default.
• W1978111504 hasConceptScore W1978111504C2778820342 @default.
• W1978111504 hasConceptScore W1978111504C2779438470 @default.
• W1978111504 hasConceptScore W1978111504C2780333294 @default.
• W1978111504 hasConceptScore W1978111504C42362537 @default.

• next